First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients

1. Salazar, F.
2. Molina, M.A.
3. Sanchez-Ronco, M.
4. Moran, T.
5. Ramirez, J.L.
6. Sanchez, J.M.
7. Stahel, R.
8. Garrido, P.
9. Cobo, M.
10. Isla, D.
11. Bertran-Alamillo, J.
12. Massuti, B.
13. Cardenal, F.
14. Manegold, C.
15. Lianes, P.
16. Trigo, J.M.
17. Sanchez, J.J.
18. Taron, M.
19. Rosell, R.